Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model

International Journal of Antimicrobial Agents

Volumn 25, Issue 6, 2005, Pages 530-534

  Dandekar, Prachi K ^a   Williams, Peter ^a   Tessier, Pamela R ^a   Farrell, David J ^b   Nightingale, Charles H ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b GR Micro   (United Kingdom)

Author keywords

Antimicrobial resistance; Experimental infection model; Ribosomal mutation; S. pneumoniae; Telithromycin

Indexed keywords

AZITHROMYCIN; TELITHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM COLONY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RIBOSOME; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; GENES, RRNA; KETOLIDES; LUNG; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MUTATION; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 19544384399     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.02.014     Document Type: Article

References (18)

1. P.C. Appelbaum Resistance among Streptococcus pneumoniae: implications for drug selection Clin Infect Dis 34 2002 1613 1620
2. D.J. Farrell, S. Douthwaite, and I. Morrissey Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study Antimicrob Agents Chemother 47 2003 1777 1783
3. K. Tateda, K. Takashima, and Miyazaki Noncompromised penicillin resistant pneumococcal pneumonia CBA/J model and comparative efficacies of antibiotics in this model Antimicrob Agents Chemother 40 1996 1520 1525
4. P.R. Tessier, M.K. Kim, and W. Zhou Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia Antimicrob Agents Chemother 46 2002 1425 1434
5. P.R. Tessier, H.M. Mattoes, and P.K. Dandekar Pharmacodynamic profile of telithromycin against macrolide and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic thigh infection model Antimicrob Agents Chemother 49 2005 188 1894
6. G. Drusano Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin Clin Microbiol Infect 7 2001 24 29
7. F. Namour, D.H. Wessels, and M.H. Pascual Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses Antimicrob Agents Chemother 45 2001 170 175
8. C. Carbon, S. Moola, and I. Velancsics Telithromycin (HMR 3647), a new once-daily ketolide antimicrobial, provides effective treatment of community-acquired pneumonia Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000 American Society for Microbiology Washington, DC, USA 490 [Abstract 2245]
9. C. Perret, B. Lenfant, and E. Weinling Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers Chemotherapy 48 2002 217 223
10. H.L. Hoffman, M.E. Klepser, and E.J. Ernst Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model Antimicrob Agents Chemother l47 2003 739 746
11. D. Felmingham Evolving resistance pattern in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin J Infect 44 2002 3 10
12. I. Odenholt, E. Lowdin, and O. Cars Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens Antimicrob Agents Chemother 45 2001 23 29
13. A. Bonnefoy, M. Guitton, and C. Delachaume In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models Antimicrob Agents Chemother 45 2001 1688 1692
14. A. Bonnefoy, and P. Le Priol Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics J Antimicrob Chemother 47 2001 471 473
15. H. Okamoto, S. Miyazaki, and K. Tateda In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae Antimicrob Agents Chemother 45 2001 3250 3252
16. L. Piroth, N. Desbiolles, and V. Mateo-Ponce HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae J Antimicrob Chemother 47 2001 33 42
17. C.M. Fogarty, S. Kohno, and P. Buchanan Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin J Antimicrob Chemother 51 2003 947 955
18. B. Capitano, D. Maglio, and M.A. Banevicius Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model Int J Antimicrob Agents 22 2003 588 593